GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT04965636
- Locations
- 🇹🇷
GSK Investigational Site, Kayseri, Turkey
A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy Adult Participants Under Fasting Conditions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT04964050
Long-term Follow-up Study to Evaluate Durability of Sustained Virologic Response (SVR) in Previous GSK3228836 Study Participants (B-Sure)
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 450
- Registration Number
- NCT04954859
- Locations
- 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 238
- Registration Number
- NCT04950127
- Locations
- 🇬🇧
GSK Investigational Site, Surrey, United Kingdom
An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.
- Conditions
- Herpes Genitalis
- Interventions
- Procedure: Blood samplingProcedure: Anogenital lesion swab collection
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 537
- Registration Number
- NCT04950712
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 359
- Registration Number
- NCT04937387
- Locations
- 🇨🇳
GSK Investigational Site, Zunyi, China
A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Device: ELLIPTA
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 229
- Registration Number
- NCT04923347
- Locations
- 🇮🇳
GSK Investigational Site, Pune, India
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 43
- Registration Number
- NCT04915755
- Locations
- 🇬🇧
GSK Investigational Site, Wigan., United Kingdom
Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Standard therapy
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 65
- Registration Number
- NCT04908865
- Locations
- 🇨🇳
GSK Investigational Site, Xi'an, China
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: Placebo
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26668
- Registration Number
- NCT04886596
- Locations
- 🇬🇧
GSK Investigational Site, Witney, United Kingdom